第二条 提名委员会是董事会按照《公司章程》设立的专门工作机构，主要 负责对公司董事和高级管理人员的人选、选择标准和程序进行审查并提出建议。 第二章 人员组成 第三条 提名委员会由三至五名董事组成，其中独立董事应占多数并担任召 集人。 第四条 提名委员会成员由董事长、二分之一以上独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第一章 总则 第一条 为规范河北常山生化药业股份有限公司（以下简称公司）董事及高 级管理人员的产生，优化董事会成员的组成，完善公司治理结构，根据《中华人 民共和国公司法》（以下简称公司法）《上市公司治理准则》《河北常山生化药业 股份有限公司章程》（以下简称《公司章程》）及其他有关规定，公司设立董事会 提名委员会，并制定本实施细则。 河北常山生化药业股份有限公司 董事会提名委员会工作实施细则 （一）拟定公司董事、高级管理人员的选择标准和程序，对公司董事、高级 管理人员人选及其任职资格进行遴选、审核，并就下列事项向董事会提出建议： （1）提名或者任免董事； 第五条 提名委员会设主任委员（召集人）一名，由独立董事委员担任。 第六条 提名委员会委员任期与同届董事会董事的任期一致，连选可 ...

第五条 对于没有法律法规依据要求报送统计报表的单位向公司索要统计 报表或涉及销售收入、利润等敏感信息的资料，公司应拒绝报送。 第一条 为规范与加强河北常山生化药业股份有限公司(以下简称公司)对 定期报告、临时报告及重大事项在筹划、编制、审议和待披露期间的外部信息报 送和使用管理，依据《中华人民共和国证券法》、《深圳证券交易所创业板股票上 市规则》、《上市公司信息披露管理办法》、《上市公司治理准则》、《河北常山生化 药业股份有限公司章程》和《信息披露管理制度》等有关规定，制定本制度。 第二条 本制度适用于公司各部门。 第三条 本制度所指信息是指所有对公司股票交易价格可能产生影响的信 息，包括但不限于定期报告、临时公告、财务快报、统计数据、需报批的重大事 项等。 第四条 公司的董事和高级管理人员及其他相关内幕知情人员在定期报告 编制、公司重大事项筹划期间，负有保密义务。定期报告、临时报告公布前，不 得以任何形式、任何途径向外界或特定人员泄漏定期报告、临时报告的内容，包 括但不限于业绩座谈会、分析师会议、接受投资者调研座谈等方式。 河北常山生化药业股份有限公司 对外报送信息管理制度 第六条 公司依照统计、税收征管等 ...

Core Insights - The company reported a third-quarter revenue of 190 million, a year-on-year decrease of 12.32% [1] - The net profit for the third quarter was a loss of 15.73 million, representing a decline of 129.02% [1] - For the first three quarters, the company achieved a revenue of 681 million, down 13.11% year-on-year [1] - The net profit for the first three quarters was a loss of 44.82 million, a significant decline of 714.77% [1]

证券代码：300255 证券简称：常山药业 公告编号：2025-44 河北常山生化药业股份有限公司 关于修订《公司章程》及相关议事规则的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 河北常山生化药业股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日 召开第六届董事会第四次会议，审议并通过了《关于修订<公司章程>及相关议 事规则的议案》，具体情况如下： 一、修订《公司章程》及相关议事规则的原因 为全面贯彻落实最新法律法规和监管规定要求，进一步规范公司运作机制， 完善公司治理结构，根据《公司法》《上市公司章程指引》及《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》等最新法律法规和 规范性文件的要求，并结合公司实际情况，公司对《公司章程》及其附件《股东 会议事规则》《董事会议事规则》进行修订。 二、本次《公司章程》修订情况 | 原章程 | 修订后章程 | | --- | --- | | 指公司的总经理、副总经理、财务总监、及 | 指公司的总经理、副总经理、财务总监、董 | | 董事会秘书。 | 事会秘书和本章程规定的 ...

证券代码：300255 证券简称：常山药业 公告编号：2025-42 第六届监事会第四次会议决议公告 本公司及其监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 河北常山生化药业股份有限公司（以下简称"公司"）第六届监事会第四次 会议于2025年10月29日在公司办公楼会议室以现场方式召开。本次会议于2025 年 10 月 19 日以邮件或直接送达的方式确保每一位监事收到本次会议通知。与会 的各位监事均已知悉与所议事项相关的必要信息。会议应参与表决监事 3 名，实 际参与表决监事 3 名。本次会议由公司监事会主席宗庆松先生主持，符合《公司 法》及《公司章程》等规定。 二、监事会会议审议情况 河北常山生化药业股份有限公司 1．审议通过《关于<公司 2025 年第三季度报告>的议案》 监事会认为董事会编制和审核公司 2025 年第三季度报告的程序符合法律、 行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际 情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 票同意；0 票反对；0 票弃权。 三、备查文件 1．第六届 ...

Financial Performance - Q3 2025 revenue was CNY 189,613,515.77, a decrease of 12.32% year-over-year[4] - Net profit attributable to shareholders was CNY -15,728,432.84, down 129.02% compared to the same period last year[4] - Basic and diluted earnings per share were both CNY -0.02, reflecting a decline of 133.33% year-over-year[4] - Total operating revenue decreased to ¥681,221,459.23 from ¥784,021,902.08, representing a decline of approximately 13.1% year-over-year[19] - Net profit for the period was -¥56,983,632.04, compared to -¥27,806,023.52 in the previous period, indicating a worsening of approximately 104.1%[20] - The total comprehensive income for the period was -¥57,237,822.00, compared to -¥27,804,018.75 in the previous period, indicating a decline of approximately 106.5%[20] - The company reported a basic earnings per share of -¥0.05, compared to ¥0.01 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,657,584,588.98, an increase of 2.98% from the end of the previous year[4] - The total assets of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. as of September 30, 2025, amounted to CNY 4,657,584,588.98, an increase from CNY 4,522,760,540.58 at the beginning of the period[16] - Current assets totaled CNY 2,077,304,073.35, up from CNY 2,002,412,631.48 at the beginning of the period, reflecting a growth of approximately 3.9%[16] - Total liabilities rose to CNY 3,179,083,140.13 from CNY 2,987,021,269.73, reflecting an increase of about 6.4%[17] - The company's equity remained stable with total equity at CNY 1,478,501,448.85, unchanged from the previous period[17] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 142,350,749.85, down 5.32%[4] - Cash flow from operating activities generated ¥142,350,749.85, down from ¥150,346,631.17, a decrease of about 5.3% year-over-year[21] - Cash flow from investing activities increased by 39.04% year-over-year, mainly due to reduced cash payments for fixed assets and other long-term assets[10] - Net cash flow from investing activities was -$72.1 million, an improvement from -$118.3 million year-over-year[22] - Cash inflow from financing activities totaled $2.07 billion, compared to $1.71 billion in the previous year[22] - Cash outflow from financing activities was $2.13 billion, up from $1.65 billion year-over-year[22] - Net cash flow from financing activities was -$61.9 million, a decline from a positive $51.0 million in the previous year[22] - The net increase in cash and cash equivalents was $11.2 million, down from $83.3 million year-over-year[22] - The ending balance of cash and cash equivalents was $247.0 million, compared to $314.2 million at the end of the previous year[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,618[11] Strategic Focus - The company plans to continue focusing on R&D for new products and technologies to enhance market competitiveness[15] - Future guidance indicates a strategic emphasis on market expansion and potential mergers and acquisitions to drive growth[15] Operational Efficiency - Sales expenses decreased by 64.22% year-over-year, attributed to the inclusion of products in national procurement and adjustments in sales strategy[9] - Investment income increased by 100.00% year-over-year due to gains from the disposal of a subsidiary[9] - Research and development expenses increased slightly to ¥24,568,492.79 from ¥23,438,244.55, reflecting a growth of approximately 4.8%[19] - Other income decreased significantly to ¥5,567,369.76 from ¥30,589,042.11, a decline of about 81.8% year-over-year[19] - The company recorded credit impairment losses of ¥7,201,497.18, up from ¥531,492.70, marking an increase of approximately 1255.5% year-over-year[20] Inventory and Receivables - Accounts receivable rose to CNY 310,502,510.21 from CNY 253,625,332.05, indicating an increase of approximately 22.4%[16] - Inventory decreased to CNY 1,341,817,413.22 from CNY 1,385,747,770.05, showing a decline of about 3.2%[16] Borrowings - Short-term borrowings increased by 47.98% compared to the beginning of the period, indicating a rise in borrowing[7] - Short-term borrowings increased significantly to CNY 1,313,433,777.78 from CNY 887,546,719.51, marking an increase of approximately 48.0%[17] Audit Status - The third quarter financial report was not audited[23]

Core Points - The Shanghai Composite Index closed at 3991.35 points, above the five-day moving average, with an increase of 1.04% [1] - The total trading volume of A-shares reached 1,576.01 billion yuan [1] - A total of 722 A-shares have prices that surpassed the five-day moving average, indicating a positive market trend [1] Summary by Category Stock Performance - Notable stocks with significant deviations from the five-day moving average include Longzhu Technology (15.40%), Yongfu Co., Ltd. (14.16%), and Pioneer New Materials (13.24%) [1] - Longzhu Technology saw a daily increase of 20.22%, with a turnover rate of 12.58% [1] - Yongfu Co., Ltd. increased by 19.98%, with a turnover rate of 9.37% [1] - Pioneer New Materials rose by 18.01%, with a turnover rate of 27.91% [1] Market Trends - Stocks with smaller deviations from the five-day moving average include Aibulu, Xinhua Medical, and Yunnan Baiyao, which have just crossed the five-day moving average [1] - The overall market sentiment appears to be bullish, as indicated by the number of stocks surpassing their five-day moving averages [1] Trading Data - The trading data for stocks that broke the five-day moving average includes various metrics such as daily price changes, turnover rates, and the latest prices compared to the five-day moving average [1][2] - The table provided lists multiple stocks with their respective performance metrics, highlighting the active trading environment [2]

Group 1 - The company, Changshan Pharmaceutical, stated on October 21 that it will announce any significant progress regarding the上市申请 (listing application) for Aibennapeptide according to relevant regulations [2]

Group 1 - The company, Changshan Pharmaceutical, reported that as of October 20, 2025, the number of its shareholders is 45,431 [2]

Core Insights - The stock price of Changshan Pharmaceutical has increased by 160.63% year-to-date, with a recent rise of 7.36% over the last five trading days [2] - The company has a market capitalization of 47.883 billion yuan and reported a trading volume of 7.47 billion yuan on October 21 [1] - Changshan Pharmaceutical's main business includes the research, production, and sales of heparin series products, with revenue composition of 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [2] Financial Performance - For the first half of 2025, Changshan Pharmaceutical achieved operating revenue of 492 million yuan, a year-on-year decrease of 13.42%, while the net profit attributable to the parent company was -29.09 million yuan, an increase of 37.98% year-on-year [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.5953 million yuan distributed over the last three years [3] Shareholder Information - As of October 10, 2023, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04% from the previous period, with an average of 20,094 circulating shares per person, an increase of 2.08% [2] - Hong Kong Central Clearing Limited is the fourth largest circulating shareholder, holding 10.5521 million shares, an increase of 8.0391 million shares from the previous period [3]